Early research indicate that this peptide – a dual agonist of GLP-1 and glucose-dependent insulinotropic polypeptide receptors – presents a substantial improvement in body reduction efforts . Beyond existing therapies, this dual-action compound seems to affect appetite and energy expenditure by